503 related articles for article (PubMed ID: 34105456)
1. [The Relationship between Body Mass Index and Adult Acute Myeloid Leukemia].
Wang YN; Wei T; Xi YM; Yang MY; Niu L; Wang XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):677-684. PubMed ID: 34105456
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.
Wenzell CM; Gallagher EM; Earl M; Yeh JY; Kusick KN; Advani AS; Kalaycio ME; Mukherjee S; Tiu RV; Maciejewski JP; Sekeres MA
Am J Hematol; 2013 Oct; 88(10):906-9. PubMed ID: 23828018
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
Zhang CX; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Wei SN; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):383-387. PubMed ID: 35680595
[No Abstract] [Full Text] [Related]
5. Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight.
Bray WM; Bivona C; Rockey M; Henry D; Grauer D; Abhyankar S; Aljitawi O; Ganguly S; McGuirk J; Singh A; Lin TL
Cancer Chemother Pharmacol; 2015 Oct; 76(4):691-7. PubMed ID: 26231954
[TBL] [Abstract][Full Text] [Related]
6. Body mass index is a prognostic factor in adult patients with acute myeloid leukemia.
Ando T; Yamazaki E; Ogusa E; Ishii Y; Yamamoto W; Motohashi K; Tachibana T; Hagihara M; Matsumoto K; Tanaka M; Hashimoto C; Koharazawa H; Fujimaki K; Taguchi J; Fujita H; Kanamori H; Fujisawa S; Nakajima H;
Int J Hematol; 2017 May; 105(5):623-630. PubMed ID: 28110409
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
Qin TJ; Xu ZF; Fang LW; Zhang HL; Zhang Y; Wang JZ; Pan LJ; Hu NB; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1277-82. PubMed ID: 22040988
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia].
Zhang Y; Yao XM; Zhu SL; Suo SS; Mao LP; Wei JY; Yu WJ; Mai WY; Tong HY; Meng HT; Qian WB; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):682-7. PubMed ID: 27587250
[TBL] [Abstract][Full Text] [Related]
9. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
10. Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.
Harada K; Doki N; Hagino T; Miyawaki S; Ohtake S; Kiyoi H; Miyazaki Y; Fujita H; Usui N; Okumura H; Miyamura K; Nakaseko C; Fujieda A; Nagai T; Yamane T; Sakamaki H; Ohnishi K; Naoe T; Ohno R; Ohashi K
Ann Hematol; 2018 Jan; 97(1):73-81. PubMed ID: 29196987
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of IA regimen containing different doses of idarubicin in de-novo acute myeloid leukemia for adult patients].
Sun AN; Tian XP; Cao XS; Ouyang J; Gu J; Xu KL; Yu K; Zeng QS; Sun ZM; Chen GA; Gao SJ; Zhou J; Wang JH; Yang LH; Luo JM; Zhang M; Guo XH; Wang XM; Zhang X; Shi KQ; Sun H; Ding XM; Hu JD; Zheng RJ; Zhao HG; Hou M; Wang X; Chen FP; Zhu Y; Liu H; Huang DP; Liao AJ; Ma LM; Su LP; Liu L; Zhou ZP; Huang XB; Sun XM; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1017-1023. PubMed ID: 29365393
[No Abstract] [Full Text] [Related]
12. [Analysis of induction efficacy and prognostic factors in FLT3-ITD positive acute myeloid leukemia in the real world].
Jia JS; Zhu HH; Gong LZ; Zhao T; Wang J; Jiang Q; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):398-403. PubMed ID: 31207705
[No Abstract] [Full Text] [Related]
13. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of Different Doses of Daunorubicin Induced Chemotherapy in Patients with Newly Diagnosed Primary Acute Myeloid Leukemia Under 65 Years Old].
Gong SG; Wang FJ; Wang ST; Zheng Q; Shuai X; Ma HB; Zhang L; Chen XC; Wu Y; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1071-1079. PubMed ID: 34362484
[TBL] [Abstract][Full Text] [Related]
15. A comparative research on obesity hypertension by the comparisons and associations between waist circumference, body mass index with systolic and diastolic blood pressure, and the clinical laboratory data between four special Chinese adult groups.
Wu O; Leng JH; Yang FF; Yang HM; Zhang H; Li ZF; Zhang XY; Yuan CD; Li JJ; Pan Q; Liu W; Ren YJ; Liu B; Liu QM; Cao CJ
Clin Exp Hypertens; 2018; 40(1):16-21. PubMed ID: 29083240
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.
Jahic A; Iljazovic E; Hasic S; Arnautovic AC; Sabitovic D; Mesanovic S; Sahovic H; Simendic V
Med Arch; 2017 Feb; 71(1):20-24. PubMed ID: 28428668
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of 10 mg/m² or 8 mg/m² idarubicin plus cytarabine regimen as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia].
Zhang Y; Yang S; Wang J; Zhu H; Bao L; Jia J; Zhao T; Jiang H; Lu J; Jiang B; Huang X; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):225-9. PubMed ID: 25854467
[TBL] [Abstract][Full Text] [Related]
18. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Chen Y; Yang T; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Hu J
Medicine (Baltimore); 2016 Jul; 95(30):e4182. PubMed ID: 27472687
[TBL] [Abstract][Full Text] [Related]
19. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
[TBL] [Abstract][Full Text] [Related]
20. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
